Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia

British Journal of Haematology

Volumn 156, Issue 3, 2012, Pages 402-404

  Haskova, Zdenka ^a   Whitacre, Margaret N ^a   Dede, Kimberly A ^a   Lee, Judithann M ^a   Trulli, Stephen H ^a   Ciucci, Marc ^a   Toso, John F ^a   White, John R ^a   Jonak, Zdenka L ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Bendamustine; Chronic lymphocytic leukaemia; Combination therapy; Ofatumumab; Tumour xenograft

Indexed keywords

BENDAMUSTINE; CD20 ANTIGEN; MONOCLONAL ANTIBODY; OFATUMUMAB; RITUXIMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SIZE; CELL SPECIFICITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; IN VIVO STUDY; LETTER; LEUKEMIA CELL LINE; LYMPHOMA; LYMPHOMA CELL LINE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; MICE, SCID; NITROGEN MUSTARD COMPOUNDS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84855814866     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08829.x     Document Type: Letter

References (10)

1. Aivado, M., Schulte, K., Henze, L., Burger, J., Finke, J. & Haas, R. (2002) Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Seminars in Oncology, 29, 19-22.
2. Chow, K.U., Sommerlad, W.D., Boehrer, S., Schneider, B., Seipelt, G., Rummel, M.J., Hoelzer, D., Mitrou, P.S. & Weidmann, E. (2002) Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica, 87, 33-43.
3. Friedberg, J.W. (2009) Bendamustine in chronic lymphocytic leukemia: the future is combination therapy. Leukaemia & Lymphoma, 50, 1399-1400.
4. de Haij, S., Jansen, J.H., Boross, P., Beurskens, F.J., Bakema, J.E., Bos, D.L., Martens, A., Verbeek, J.S., Parren, P.W., van de Winkel, J.G. & Leusen, J.H. (2010) In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Research, 70, 3209-3217.
5. Hallek, M. (2009) State-of-the-art treatment of chronic lymphocytic leukemia. Hematology American Society of Hematology Education Program, 1, 440-449.
6. Iannitto, E., Morabito, F., Mancuso, S., Gentile, M., Montanini, A., Augello, A., Bongarzoni, V., D'Arco, A., Di Renzo, N., Fazzi, R., Franco, G., Marasca, R., Mule, A., Musso, M., Musto, P., Pennese, E., Piccin, A., Rota-Scalabrini, D., Visani, G. & Rigacci, L. (2010) Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study. British Journal of Haematology, 153, 351-357.
7. Lin, T.S. (2010) New agents in chronic lymphocytic leukemia. Current Hematologic Malignancy Reports, 5, 29-34.
8. Reagan, J.L. & Castillo, J.J. (2010) Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia. Expert Review of Anticancer Therapy, 11, 151-160.
9. Tsimberidou, A.M. (2010) Ofatumumab in the treatment of chronic lymphocytic leukemia. Drugs Today (Barc), 46, 451-461.
10. Zhang, L., Qian, Z., Cai, Z., Sun, L., Wang, H., Bartlett, J.B., Yi, Q. & Wang, M. (2009) Synergistic antitumour effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. American Journal of Hematology, 84, 553-559.